Results 151 to 160 of about 3,887,212 (164)

Peptide Receptor Radionuclide Therapy [PDF]

Journal of Clinical Endocrinology and Metabolism, 2022
The concept of using a targeting molecule labeled with a diagnostic radionuclide for using positron emission tomography or single photon emission computed tomography imaging with the potential to demonstrate that tumoricidal radiation can be delivered to
Tessa Brabander, Johannes Hofland, Frederik Verburg   +2 more
exaly   +3 more sources

Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT)

Endocrine Pathology, 2020
Peptide Receptor Radionuclide Therapy (PRRT) is an emerging therapeutic option for pancreatic neuroendocrine tumors (PanNETs). A possible role for PRRT as a neoadjuvant agent is still largely undetermined, explored only in case reports or small case ...
Stefano Partelli, Massimo Falconi, Claudio Doglioni   +2 more
exaly   +2 more sources

Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC

Cancer Biotherapy and Radiopharmaceuticals, 2009
Purpose: Peptide-receptor radionuclide therapy (PRRT) with somatostatin analogs is an efficient new tool in patients with neuroendocrine tumors, with low risk of toxicity.
Lisa Bodei, Giovanni Paganelli, Maddalena Sansovini   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Peptide receptor radionuclide therapy in neuroendocrine neoplasms and related tumors: from fundamentals to personalization and the newer experimental approaches

Expert Review of Precision Medicine and Drug Development, 2023
Sandip Basu
exaly  

Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival

European Journal of Nuclear Medicine and Molecular Imaging, 2020
Maythinee Chantadisai, R P Baum
exaly  

Peptide receptor radionuclide therapy (PRRT) for GEP-NETs

Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012
Guido Krenning, Peeters Robin, Wouter W de Herder   +2 more
exaly  

Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward

Current Topics in Medicinal Chemistry, 2020
Julie Nonnekens, Marion de Jong
exaly  

Repeated cycles of peptide receptor radionuclide therapy (PRRT) – Results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET

Radiotherapy and Oncology, 2012
Anna Sowa-Staszczak, Dariusz Pawlak, Renata Mikołajczak   +2 more
exaly  

Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy

Pharmaceuticals, 2019
Ute Hennrich, Klaus Kopka
exaly  

Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial

European Journal of Nuclear Medicine and Molecular Imaging, 2018
Jean-Mathieu Beauregard, Michela del Prete   +1 more
exaly